Gunderson Dettmer Steers Vaccine Biz's $120M Financing
Clinical-stage biotechnology company Affinivax said Thursday it raised $120 million from investors to advance its vaccine platform with guidance from Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP....To view the full article, register now.
Already a subscriber? Click here to view full article